Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects

This study has been completed.
Information provided by:
Valeant Pharmaceuticals International, Inc. Identifier:
First received: April 3, 2006
Last updated: July 22, 2011
Last verified: July 2011
This is the first multiple-dose experience in humans with MOA-728 in an oral formulation. This study will provide an assessment of the safety, tolerability, and pharmacokinetics (PK) of MOA-728 following administration of ascending multiple oral doses to healthy subjects.

Condition Intervention Phase
Postoperative Complications
Drug: MOA-728
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Official Title: Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of MOA-728 Administered Orally to Healthy Subjects

Further study details as provided by Valeant Pharmaceuticals International, Inc.:

Primary Outcome Measures:
  • Safety

Estimated Enrollment: 48
Study Start Date: March 2006
Estimated Study Completion Date: August 2006

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy men and women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00311350

United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19148
Sponsors and Collaborators
Valeant Pharmaceuticals International, Inc.
Study Director: Jeff Cohn Valeant Pharmaceuticals International, Inc.
  More Information

Responsible Party: Jeff Cohn, Salix Pharmaceuticals Identifier: NCT00311350     History of Changes
Other Study ID Numbers: 3200A3-100
Study First Received: April 3, 2006
Last Updated: July 22, 2011

Keywords provided by Valeant Pharmaceuticals International, Inc.:

Additional relevant MeSH terms:
Postoperative Complications
Signs and Symptoms, Digestive
Signs and Symptoms
Pathologic Processes processed this record on May 25, 2017